SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, announced today that the company's
President and CEO Theodore Schroeder will present the company's corporate
overview at the following investment conferences:
-- Bank of America's 2008 Specialty Pharmaceuticals Conference at the
Southampton Inn, Long Island, New York on Thursday, August 7, 2008 at
1:35pm Eastern Time (10:35am Pacific Time)
-- Canaccord Adams' 28th Annual Global Growth Conference at the
InterContinental Hotel in Boston on Tuesday, August 12 at 9:00am
Eastern Time (6:00am Pacific Time)
Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence
Contacts: William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved